Learn

Although coronavirus disease 2019 (COVID‐19) appears to be less common in children, with milder disease overall, severe complications may occur, including paediatric inflammatory multisystem syndrome (PIMS‐TS).

Recognising the distinct needs of this population, the National COVID‐19 Clinical Evidence Taskforce formed a Paediatric and Adolescent Care Panel to provide living guidelines for Australian clinicians to manage children and adolescents with COVID‐19 and COVID‐19 complications.

Living guidelines mean that these evidence‐based recommendations are updated in near real time to give reliable, contemporaneous advice to Australian clinicians providing paediatric care.

This MJA guideline summary shares more.

Details

1. Explain key components of the guideline.
2. List main recommendations.
3. Recognise changes in management as a result of the guideline.

Authors: David Fraile Navarro, Britta Tendal and David Tingay

Article Type: Guideline summary